PROSPECTs Futile For Bavarian Nordic's Prostvac Cancer Vaccine
The Phase III PROSPECT study's data monitoring committee decides against continuing after interim analysis. The fall-out could hit Bavarian Nordic’s CV301 too.
You may also be interested in...
Buying two vaccines for rabies and tick-borne encephalitis complements the recently approved smallpox and monkeypox vaccine Jynneos. Now the Danish firm needs to start selling them.
Nigeria's monkeypox outbreak represents opportunity for Danish company still looking to overcome cancer vaccine setback.
The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.